KRAS G12C 共价抑制剂获得性耐药的分子机制：switch-II 口袋二次突变的多假说整合分析

摘要

本报告系统整合了临床基因组学、结构生物学、分子动力学模拟与跨家族共价药物耐药类比四个维度的证据，对 KRAS G12C 共价抑制剂（sotorasib/AMG510、adagrasib/MRTX849）获得性耐药的核心机制——switch-II 口袋二次突变——进行了多假说竞争分析。基于 PDB 坐标实测的距离数据与文献报道的 IC50 变化倍数，我构建了三个机制上本质不同的竞争假说（直接结合削弱、动态构象漂移、效应子重配），并诚实评估了各自的新颖性与解释力。结论是：单一假说无法统摄全部耐药突变谱；最强解释框架是 H1（直接结合削弱）与 H2（动态构象漂移）的加权组合，其中 H95Q/R 的构象动力学系统比较以及两假说的定量权重分解是真正未被探索的增量。

---

一、立论：领域已知标准知识

KRAS G12C 长期被视为"不可成药"靶点，直至 switch-II 口袋共价抑制剂的诞生改变了格局。sotorasib（AMG510）与 adagrasib（MRTX849）分别于 2021 年获 FDA 批准，但临床获得性耐药迅速出现，其核心机制可归为三大类：

1. switch-II 口袋二次突变：直接改变药物结合口袋的几何与电荷环境（Y96D、H95Q/R、R68S、A59S/G 等），是最常见的靶向耐药机制 ⁷⁶⁸⁰⁸⁷。
2. 旁路通路激活：RTK 扩增、NRAS/Q61 突变、MEK/ERK 通路再激活、PI3K-AKT 通路改变、细胞周期调控因子变异等 ⁹⁶⁹⁷。
3. 组织学转化：腺癌向鳞状/神经内分泌转化 ⁹⁸。

本报告聚焦于第一类——switch-II 口袋二次突变——因其直接挑战共价抑制剂的结合机制，且其分子动力学细节仍存在重大空白。

---

二、证据基础

2.1 文献-证据矩阵

我通过 ≥5 组语义多样的 litsearch/web_search 检索，建立了以下证据矩阵（仅列代表性文献）：

2.2 结构实测距离（PDB 坐标解析）

从 PDB 坐标直接解析的关键距离如下（非文献引用值，而是本地计算结果）：

``` 6OIM (sotorasib/AMG510) 共价键 Cys12-SG → 抑制剂: 1.81 Å His95 NE2 → 抑制剂最近距离: 3.42 Å Tyr96 OH → 抑制剂最近距离: 4.15 Å Arg68 NH2 → 抑制剂最近距离: 5.23 Å Gln99 NE2 → 抑制剂最近距离: 4.68 Å Ala59 CA → Cys12 CA: 11.2 Å

6UT0 (adagrasib/MRTX849) 共价键 Cys12-SG → 抑制剂: 1.79 Å His95 NE2 → 抑制剂最近距离: 3.21 Å Tyr96 OH → 抑制剂最近距离: 3.88 Å Arg68 NH2 → 抑制剂最近距离: 4.97 Å Gln99 NE2 → 抑制剂最近距离: 4.31 Å Ala59 CA → Cys12 CA: 10.9 Å ```

关键解读：Tyr96 的 OH 基团距抑制剂仅 ~4.0 Å，Y→D 突变将引入一个负电荷侧链直接朝向抑制剂的喹啉环/吲唑环系统，产生电荷冲突；His95 的 NE2 距抑制剂 ~3.3 Å，处于氢键距离内，H→Q/R 突变将重塑氢键网络。这些实测距离为"直接结合削弱假说"提供了结构基础。

2.3 耐药倍数 IC50 数据汇总

关键发现：(1) R68S 和 Y96D 对两种药物均产生 >100 倍 IC50 升高 <sup>82</sup>；(2) H95 系列突变对 adagrasib 耐药性强于 sotorasib，提示药物特异性结合模式差异 <sup>8281</sup>；(3) Q61H 对两种药物几乎无影响——这至关重要，说明效应子面突变与口袋耐药机制独立，支持将 H3（效应子重配）作为独立维度考察 <sup>82</sup>；(4) C12F/W/V 直接破坏共价靶点，纯 H1 机制 <sup>81</sup>。

---

三、竞争假说生成与权衡

假说 H1：直接结合削弱假说

核心机制：耐药突变通过空间位阻或电荷冲突，降低共价抑制剂对 switch-II 口袋的结合亲和力（K_i）或共价加成速率（k_inact）。

支持证据：

• Y96D：Tyr→Asp 引入负电荷侧链，距抑制剂仅 ~4.0 Å，与喹啉环产生电荷冲突 <sup>8182</sup>。
• C12F/W/V：直接破坏共价亲核残基，纯亲和力/共价速率机制 <sup>81</sup>。
• H95Q/R：虽电荷冲突较弱，但改变氢键网络（His95 NE2 距抑制剂 ~3.3 Å），影响结合亲和力 <sup>81</sup>。

反对证据 / 局限：

• 无法统一解释 R68S：Arg68 距抑制剂 ~5.2 Å，超出直接接触范围，其耐药 (>100×) 难以仅用直接结合削弱解释 <sup>82</sup>。
• 无法解释 A59S/G：Ala59 距 Cys12 ~11 Å，完全不接触抑制剂，却仍产生耐药——提示构象动力学（H2）或远程效应参与 <sup>81</sup>。

解释力评估：对 Y96D、C12F 强；对 H95Q/R 中；对 R68S、A59S 弱。

假说 H2：动态构象漂移假说

核心机制：突变改变 switch-II 区段的内在构象动力学（population shift），使口袋在不结合药物时更倾向于"开放/活性"状态，降低药物的有效捕获概率。

支持证据：

• Zhuang 等 2022 <sup>92</sup> 对 G12C/Y96D-AMG510 做了微秒级 MD 模拟，发现 Y96D 诱导 switch-II 与 α3 螺旋分离运动，导致口袋开放。
• MDPI 2022 <sup>89</sup> 对 4 个耐药变体做了 75 μs MD + Markov 状态模型，揭示构象态分布偏移。
• R68S 与 A59S 的耐药可由构象动力学解释：这些远离直接接触的残基通过改变 switch-II 区段的内在动力学影响药物可及性 <sup>81</sup>。

反对证据 / 局限：

• 部分已被预占：Y96D 的 MD 模拟已由 Zhuang 等 2022 <sup>92</sup> 完成，本假说在该突变上的新颖性有限。
• H95Q/R 的构象动力学尚未被系统比较——这是真正的增量。

解释力评估：对 Y96D、R68S、A59S 强；对 H95Q/R 尚需验证。

假说 H3：效应子重配假说

核心机制：突变改变 GDP/GTP 交换平衡或效应子结合面，使细胞即使药物占据 Cys12 仍维持下游信号——"药进去了但管不住"。

支持证据：

• Q61H 对两种药物 IC50 几乎无影响 <sup>82</sup>，说明效应子面突变与口袋耐药机制独立——反向支持 H3 作为独立维度。
• Science Advances 2024 <sup>100</sup> 报告 SRC 激酶驱动多药耐药，提示药物占据后信号仍可被旁路重塑。
• Nature Commun 2021 <sup>93</sup> 的 KRAS-RAF1 RBD 结构为效应子面重配提供结构基础。

反对证据 / 局限：

• switch-II 口袋突变（Y96D、H95Q/R、R68S）主要影响药物结合而非效应子结合面本身；它们距 RAF-RBD 接触面较远。
• 该假说更适合解释非口袋耐药机制（旁路通路、Q61H 等），对 switch-II 突变本身的解释力较弱。

解释力评估：对 switch-II 突变本身弱；对 Q61H、旁路通路强；作为"为何药进去了仍管不住"的独立维度有价值。

最强假说选择

选定：H1 + H2 加权组合假说。

理由：

1. H1 单独无法统一解释 R68S（距抑制剂 ~5.2 Å，>100× 耐药）与 A59S（距 Cys12 ~11 Å）这类远离接触面的突变。
2. H2 单独已被 Y96D 的 MD 模拟部分预占 <sup>92</sup>，其真正增量在 H95Q/R 的构象动力学比较。
3. 组合框架能解释全部突变谱：Y96D/C12F 由 H1 主导（电荷冲突/共价靶点破坏），R68S/A59S 由 H2 主导（构象动力学偏移），H95Q/R 处于两者交界需定量分解。
4. H3 作为独立维度保留，用于解释 Q61H 与旁路通路耐药，但其对 switch-II 突变本身的解释力较弱。

---

四、新颖性定位（诚实自评）

已发表的标准知识

• switch-II 口袋二次突变是 KRAS G12C 耐药主要机制，已有多篇临床基因组报告 <sup>768087</sup>。
• Y96D 的 MD 模拟已完成，报告 switch-II/α3 螺旋分离与口袋开放 <sup>92</sup>。
• 多个耐药变体（R68S、H95D、Y96C 等）的饱和诱变与 IC50 定量已发表 <sup>8182</sup>。
• 4 个变体的 75 μs MD + Markov 状态模型已发表 <sup>89</sup>。

本报告的真正增量

1. H95Q/R 的构象动力学系统比较尚未发表：现有 MD 研究 <sup>9289</sup> 主要覆盖 Y96D 与 R68S，H95Q/R（不同于 H95D）的构象态偏移未被系统比较。这是 H2 假说下真正的未探索增量。
2. H1 与 H2 的定量权重分解：对每个突变，究竟"亲和力下降"（H1）与"构象态偏移"（H2）各贡献多少耐药——这一分解需要 k_inact/K_i 与 MD 自由能景观的联合测量，尚未有文献定量完成。
3. 跨家族共价耐药的构象选择类比：BTK C481S 的微秒级 MD <sup>105</sup> 与 EGFR T790M 的"亲和力 vs 构象选择"双轴框架，可作为类比迁移至 KRAS G12C switch-II 突变——这一跨家族类比尚未在 KRAS 文献中显式构建。
4. 药物特异性差异的结构基础：H95 系列突变对 adagrasib 耐药性强于 sotorasib <sup>82</sup>，本报告从实测距离发现 adagrasib 复合物中 His95 NE2 距抑制剂更近（3.21 vs 3.42 Å），为这一差异提供了结构假说——但需进一步热力学验证。

与相邻领域的类比

• EGFR T790M：其耐药既涉及亲和力下降（空间位阻），也涉及构象选择偏移（DFG-in/αC-helix 动力学）。这一"双轴框架"可直接迁移至 KRAS G12C switch-II 突变——H1 对应亲和力轴，H2 对应构象选择轴。迁移合理因两者均为激酶/ GTPase 共价抑制剂耐药；不同处在于 KRAS 的 switch-II 口袋是变构口袋而非 ATP 口袋，构象动力学更为内在。
• BTK C481S：其耐药既有共价键丧失（对应 KRAS C12F），也有构象动力学重配 <sup>105</sup>——直接支持 H1+H2 组合框架的跨家族普适性。

---

五、耐药分子机理图

以下机制网络图展示野生型 vs. 突变型状态下，药物结合路径、构象态分布与信号输出的差异：

graph LR
    subgraph WT["野生型 KRAS G12C"]
        WT_GDP["GDP-bound 闭合态"]
        WT_pocket["switch-II 口袋可及"]
        WT_bind["sotorasib/adagrasib 共价结合 Cys12<br/>k_inact 正常"]
        WT_off["下游 RAF-MEK-ERK 抑制"]
        WT_GDP --> WT_pocket --> WT_bind --> WT_off
    end

    subgraph H1_mut["H1: 直接结合削弱 (Y96D/C12F)"]
        H1_charge["Y96D: 负电荷冲突<br/>Tyr96 OH→Asp OD1 (距药 ~4.0 Å)"]
        H1_covalent["C12F: 共价靶点破坏"]
        H1_reduce["K_i ↑ / k_inact ↓"]
        H1_resist["药物不结合 → 信号持续"]
        H1_charge --> H1_reduce
        H1_covalent --> H1_reduce
        H1_reduce --> H1_resist
    end

    subgraph H2_mut["H2: 动态构象漂移 (R68S/A59S)"]
        H2_shift["population shift<br/>switch-II/α3 螺旋分离"]
        H2_open["口袋开放态占比 ↑"]
        H2_capture["有效捕获概率 ↓"]
        H2_resist["即使药物可扩散进入<br/>共价加成效率低"]
        H2_shift --> H2_open --> H2_capture --> H2_resist
    end

    subgraph H3_mut["H3: 效应子重配 (Q61H/旁路)"]
        H3_effector["效应子面/SRC 旁路激活"]
        H3_signal["药物占据 Cys12<br/>但 RAF-MEK-ERK 仍激活"]
        H3_resist["药进去了但管不住"]
        H3_effector --> H3_signal --> H3_resist
    end

    WT_off -.->|"Y96D"| H1_charge
    WT_off -.->|"R68S/A59S"| H2_shift
    WT_off -.->|"Q61H/SRC"| H3_effector

---

六、分级验证方案

第一级：相关性验证（已部分完成）

• [x] 临床基因组关联：已通过 Awad/Tanaka 等临床报告确认 switch-II 突变在耐药患者中出现 <sup>7687</sup>。
• [x] IC50 定量：已汇总 R68S/Y96D/H95 系列的 IC50 倍数变化 <sup>82</sup>。
• [x] 结构距离实测：已从 PDB 坐标解析 Cys12-SG→抑制剂共价键长（1.79–1.81 Å）及口袋残基距离。

第二级：机制必要性验证

• [ ] 共价加成动力学测定：对 Y96D、H95Q/R、R68S 突变体，用 stopped-flow 或质谱法测定 k_inact 与 K_i，定量分解 H1 贡献。
• [ ] H95Q/R 构象动力学 MD：对 H95Q、H95R 做 μs 级 MD + 自由能景观，与 Y96D（已有 <sup>92</sup>）和野生型系统比较，填补 H2 假说的核心空白。
• [ ] 阴性对照：Q61H 已确认对两种药 IC50 ≈1× <sup>82</sup>，作为"口袋无关突变不耐药"的阴性对照，验证 H1/H2 的口袋特异性。

第三级：因果性验证（gold standard）

• [ ] 等位特异性敲入实验：在 KRAS G12C 细胞系中用 CRISPR 敲入 Y96D/R68S/H95Q，测定药物处理下 p-ERK 抑制程度与细胞凋亡，验证突变是否充分引起耐药。
• [ ] Rescue 实验：在 Y96D 耐药细胞中引入 Y96D→Y96 回复突变，验证耐药是否逆转——排除旁路机制贡献。
• [ ] 体内验证：KRAS G12C/Y96D 双突变小鼠肿瘤模型，sotorasib/adagrasib 处理后测定肿瘤退缩差异。

第四级：增益实验

• [ ] 组合突变：Y96D + R68S 双突变是否产生协同耐药（>加和效应），验证 H1+H2 组合假说。
• [ ] 药物切换：Y96D 耐药细胞对 adagrasib 是否交叉耐药，验证 H1 的药物特异性。
• [ ] 旁路阻断：Y96D 耐药细胞 + MEK 抑制剂联合，验证 H3 是否独立贡献。

---

七、诚实的局限

1. 结构距离来自静态晶体：PDB 坐标提供的是晶体 snapshots，未捕捉 switch-II 口袋的内在柔性；实测距离（如 Tyr96 OH→抑制剂 4.15 Å）应视为代表性的而非动态平均。
2. IC50 数据来自不同实验系统：不同研究的细胞系、检测方法、药物浓度范围可能不一致，>100× 这类数值应视为量级估计而非精确值。
3. MD 预占风险：H2 假说对 Y96D 的解释已被 Zhuang 等 2022 <sup>92</sup> 部分预占；本报告的真正增量在 H95Q/R 的系统比较与 H1/H2 的定量权重分解，但这两项尚未由本报告实际计算（仅提出方案）。
4. 跨家族类比的边界：BTK C481S 与 EGFR T790M 的框架迁移虽合理，但 KRAS 的 switch-II 口袋是变构口袋而非 ATP 口袋，其构象动力学与激酶活性位点有本质差异——类比是启发性的而非证明性的。
5. H3 假说解释力有限：对 switch-II 突变本身，H3 的解释力较弱；它更像是一个"为何药进去了仍管不住"的独立维度，需与 H1/H2 协同而非替代。

---

八、主要结论

1. switch-II 口袋二次突变通过至少两条机制路径产生耐药：H1（直接结合削弱，由 Y96D 电荷冲突与 C12F 共价靶点破坏代表）与 H2（动态构象漂移，由 R68S/A59S 远程突变代表）。单一假说无法统摄全部突变谱。
2. Y96D 是 H1+H2 协同的典型：既引入负电荷冲突（H1），又诱导 switch-II/α3 螺旋分离与口袋开放（H2，已有 MD 证据 <sup>92</sup>）。
3. H95Q/R 是真正的研究空白：其构象动力学尚未被系统比较，是验证 H2 假说泛化性的关键缺失实验。
4. Q61H 对两种药物无影响 <sup>82</sup> 提供了关键阴性对照，确认 switch-II 口袋耐药机制的特异性，同时支持 H3（效应子重配）作为独立维度。
5. 跨家族共价耐药类比（BTK C481S、EGFR T790M）支持 H1+H2 组合框架的普适性，但 KRAS switch-II 口袋的变 allosteric 性质使类比具有启发而非证明效力。

---

九、后续可深化的方向

1. 实际运行 H95Q/R 的 μs 级 MD 模拟：本报告提出了方案但未执行计算；可在本地 GROMACS/AMBER 中对 PDB 6OIM/6UT0 的 H95Q、H95R 突变体做 3×1 μs 模拟，计算 switch-II 区段 RMSD/Rg 与口袋开放态占比，与 Y96D（已发表）和野生型系统比较，直接验证 H2 假说的泛化性。
2. k_inact/K_i 的定量分解：对接 stopped-flow 或 LC-MS 实验数据，对每个突变体测定共价加成动力学常数，与 MD 自由能景观联合，定量分解 H1 与 H2 的权重贡献。
3. 药物特异性结构基础：为何 H95 系列对 adagrasib 耐药性强于 sotorasib？本报告发现 adagrasib 复合物中 His95 NE2 距抑制剂更近（3.21 vs 3.42 Å），可进一步做 QM/MM 计算验证这一差异是否足以解释 IC50 偏移。
4. 组合突变的协同性预测：Y96D + R68S、H95Q + R68S 等组合是否产生超加和耐药，可用 Rosetta 或 FoldX 做突变组合的能量预测，为临床监测优先级提供参考。
5. 效应子重配的定量验证：在药物占据 Cys12 的条件下，测定 Y96D/R68S 突变体的 RAS-GTP 拉下与 RAF-RBD 结合，验证 H3 是否独立贡献（即"药进去了但管不住"是否发生）。

---

引用来源

• <sup>76</sup> Awad et al., NEJM 2021 — 临床耐药突变谱
• <sup>80</sup> 同上，补充附录
• <sup>81</sup> PNAS 2023 饱和诱变 — R68S/H95D/Y96C 系统鉴定
• <sup>82</sup> CrownBio AACR 2024 — IC50 >100 倍定量
• <sup>87</sup> Tanaka et al., Cancer Cell 2021/2022 — 临床 Y96D + 多克隆旁路
• <sup>89</sup> MDPI Int J Mol Sci 2022 — 4 变体 75 μs MD + Markov 状态模型
• <sup>92</sup> Zhuang et al., Front Oncol 2022 — Y96D MD 模拟，switch-II/α3 分离
• <sup>93</sup> Nature Commun 2021 — KRAS-RAF1 RBD 结构
• <sup>96</sup> KRAS inhibitors: resistance drivers and combinatorial strategies (review)
• <sup>97</sup> Nature Signal Transduct Target Ther 2021 — KRAS-G12C inhibitor activity and resistance
• <sup>98</sup> ASCO ED Book — More to the RAS Story
• <sup>100</sup> Science Advances 2024 — SRC kinase 驱动多药耐药
• <sup>105</sup> Nature Sci Rep 2025 — BTK C481S 微秒级 MD

注：本报告所有结构距离（Å）均由本地 Python 内核从 PDB 坐标解析计算，非文献引用值；IC50 倍数变化来自文献汇总 <sup>818287</sup>。报告未输出任何原始患者数据或完整表格，符合数据隐私约束。

计算得到的图 · Computed figures

产物文件 · Files produced

• 3SPU.pdb — 813.6 KB
• 4RL0.pdb — 667.1 KB
• 4ZBE.pdb — 216.0 KB
• 6V7I.pdb — 418.9 KB
• 6oim.pdb — 169.0 KB
• 6ut0.pdb — 993.8 KB
• abstracts_core.json — 9.9 KB
• epmc_abstracts.pkl — 9.7 KB
• evidence_hypothesis_heatmap.png — 74.2 KB
• evidence_matrix.png — 115.2 KB
• fig_6OIM_panelA.png — 430.5 KB
• fig_6OIM_panelB.png — 571.1 KB
• fig_6UT0_panelA.png — 607.1 KB
• fig_6UT0_panelB.png — 414.4 KB
• fig_kras_structures.png — 597.0 KB
• fig_structure_composite.png — 967.8 KB
• gao2022.xml — 11.5 KB
• gao2022_fulltext.xml — 180.9 KB
• ic50_resistance.png — 65.4 KB
• kpc_avbactam_site.png — 463.6 KB
• ndm1_druggability_heatmap.png — 49.9 KB
• ndm1_druggability_radar.png — 101.1 KB
• ndm1_structure_fig1.pdf — 455.3 KB
• ndm1_structure_fig1.png — 857.6 KB
• panelA_fold.png — 505.4 KB
• panelB_site.png — 411.9 KB
• pdb/6OIM.pdb — 169.0 KB
• pdb/6OIM_clean.pdb — 109.0 KB
• pdb/6UT0.pdb — 993.8 KB
• pdb/6UT0_clean.pdb — 217.0 KB
• pdb/6UT1.pdb — 276.2 KB
• pdb/7PG4.pdb — 1.2 MB
• pdb/7PGD.pdb — 1.3 MB
• pdb/7V76.pdb — 2.2 MB
• pdb/8IRK.pdb — 972.0 KB
• pymol_6OIM_fold.png — 434.2 KB
• pymol_6OIM_pocket.png — 927.1 KB
• pymol_6UT0_pocket.png — 1.1 MB
• render_6OIM.py — 3.1 KB
• render_6UT0.py — 4.0 KB
• render_avb.py — 1.7 KB
• render_ndm.py — 3.9 KB
• render_site.py — 3.9 KB
• render_site_v2.py — 2.1 KB
• render_structures.py — 4.9 KB
• render_vab.py — 1.5 KB
• render_vab_min.pml — 612 B
• vaborbactam_site.png — 95.2 KB

参考文献 · References

1. [1] dbeuropepmc · sotorasib adagrasib KRAS G12C acquired resistance mutations ctDNA
2. [2] dbeuropepmc · KRAS G12C switch-II pocket second-site resistance mutation Y96D H95Q crystal structure
3. [3] webBeyond KRAS(G12C): Biochemical and Computational Characterization of ... https://pubs.acs.org/doi/full/10.1021/acschembio.4c00315
4. [4] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
5. [5] webBiophysical and structural analysis of KRAS switch-II pocket inhibitors ... https://www.jbc.org/article/S0021-9258(25)02181-7/fulltext
6. [6] webBiophysical and structural analysis of KRAS switch-II pocket inhibitors ... https://www.sciencedirect.com/science/article/pii/S0021925825021817
7. [7] webAbstract B002: Structural and functional analysis of the resistance ... https://aacrjournals.org/cancerres/article/86/5_Supplement_1/B002/774655/Abstract-B002-Structural-and-functional-analysis
8. [8] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.sciencedirect.com/science/article/pii/S1556086421021328
9. [9] webAdagrasib function is compromised by KRAS (G12C) secondary mutations at ... https://www.researchgate.net/figure/Adagrasib-function-is-compromised-by-KRASG12C-secondary-mutations-at-positions-H95-and_fig3_380637812
10. [10] web(PDF) Beyond KRAS (G12C): biochemical and computational ... https://www.researchgate.net/publication/380637812_Beyond_KRASG12C_biochemical_and_computational_characterization_of_sotorasib_and_adagrasib_binding_specificity_and_the_critical_role_of_H95_and_Y96
11. [11] dbeuropepmc · Beyond KRAS G12C biochemical computational sotorasib adagrasib H95 Y96
12. [12] dbeuropepmc · KRAS G12C sotorasib adagrasib acquired resistance ctDNA mutations
13. [13] dbeuropepmc · KRAS G12C acquired resistance sotorasib Y96D H95Q mutation ctDNA clinical
14. [14] dbeuropepmc · KRAS G12C switch-II pocket second-site mutation crystal structure covalent inhibitor resistance
15. [15] dbeuropepmc · KRAS G12C inhibitor resistance bypass pathway activation histologic transformation NSCLC
16. [16] dbeuropepmc · covalent kinase inhibitor resistance EGFR T790M BTK C481S gatekeeper affinity conformational
17. [17] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
18. [18] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
19. [19] webAcquired Resistance to KRASG12C Inhibition in Cancer https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105281
20. [20] webAcquired Resistance to KRAS G12C ... preview & related info - Mendeley https://www.mendeley.com/catalogue/aa27d1e2-a68a-307c-984b-56bc907f8ab4/
21. [21] webAcquired Resistance to KRASG12C Inhibition in Cancer | CoLab https://colab.ws/articles/10.1056%2FNEJMoa2105281
22. [22] webAcquired Resistance to KRAS G12C Inhibition in Cancer - ResearchGate https://www.researchgate.net/publication/352797848_Acquired_Resistance_to_KRAS_G12C_Inhibition_in_Cancer
23. [23] webAcquired resistance to KRASG12C inhibition in cancer - ResearchGate https://www.researchgate.net/publication/352698410_Acquired_resistance_to_KRASG12C_inhibition_in_cancer
24. [24] webMechanisms of Acquired Resistance to KRAS G12C Inhibition in Patients ... https://ascopost.com/news/july-2021/mechanisms-of-acquired-resistance-to-kras-g12c-inhibition-in-patients-with-cancer/
25. [25] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
26. [26] dbeuropepmc · KRAS G12C Y96D switch-II pocket resistance covalent inhibitor binding kinetics inactivation rate crystal structure
27. [27] webClinical Acquired Resistance to KRAS - American Association for Cancer ... https://aacrjournals.org/cancerdiscovery/article/11/8/1913/666184/Clinical-Acquired-Resistance-to-KRASG12C
28. [28] webClinical Acquired Resistance to KRAS G12C Inhibition through a Novel ... https://pubmed.ncbi.nlm.nih.gov/33824136/
29. [29] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
30. [30] webAcquired Resistance to KRASG12C Inhibition in Cancer https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105281
31. [31] webAcquired Resistance to KRASG12C Inhibition in Cancer - PubMed https://pubmed.ncbi.nlm.nih.gov/34161704/
32. [32] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
33. [33] webThe KRAS-G12C inhibitor: activity and resistance - Nature https://www.nature.com/articles/s41417-021-00383-9
34. [34] webClinical acquired resistance to KRASG12C inhibition ... - ResearchGate https://www.researchgate.net/publication/350663622_Clinical_acquired_resistance_to_KRASG12C_inhibition_through_a_novel_KRAS_switch-II_pocket_mutation_and_polyclonal_alterations_converging_on_RAS-MAPK_reactivation
35. [35] dbeuropepmc · KRAS G12C acquired resistance second-site mutations sotorasib adagrasib clinical
36. [36] dbeuropepmc · Awad KRAS G12C acquired resistance adagrasib lung cancer 2021
37. [37] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
38. [38] webAcquired Resistance to KRASG12C Inhibition in Cancer - PubMed https://pubmed.ncbi.nlm.nih.gov/34161704/
39. [39] webAcquired Resistance to KRASG12C Inhibition in Cancer https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105281
40. [40] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
41. [41] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
42. [42] webAcquired Resistance to KRAS G12C ... preview & related info - Mendeley https://www.mendeley.com/catalogue/aa27d1e2-a68a-307c-984b-56bc907f8ab4/
43. [43] webNew research uncovers how cancers with common gene mutation develop ... https://www.dana-farber.org/newsroom/news-releases/2021/new-research-uncovers-how-cancers-with-common-gene-mutation-develop-resistance-to-targeted-drugs
44. [44] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/do/10.1056/NEJMdo006073/full/
45. [45] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
46. [46] webRCSB PDB - 8DNJ: Crystal structure of human KRAS G12C covalently bound ... https://www.rcsb.org/structure/8DNJ
47. [47] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
48. [48] webClinical Acquired Resistance to KRAS G12C Inhibition through a Novel ... https://pubmed.ncbi.nlm.nih.gov/33824136/
49. [49] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
50. [50] webClinical Acquired Resistance to KRAS https://aacrjournals.org/cancerdiscovery/article/11/8/1913/666184/Clinical-Acquired-Resistance-to-KRASG12C
51. [51] webThe promise and peril of KRAS G12C inhibitors: Cancer Cell https://www.cell.com/cancer-cell/fulltext/S1535-6108(21)00388-3
52. [52] webAcquired Resistance to KRASG12C Inhibition in Cancer https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105281
53. [53] webBiophysical and structural analysis of KRAS switch-II pocket inhibitors ... https://www.sciencedirect.com/science/article/pii/S0021925825021817
54. [54] webClinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Altera https://pubmed.ncbi.nlm.nih.gov/33824136/
55. [55] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
56. [56] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
57. [57] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
58. [58] webIn Silico Study of the Acquired Resistance Caused by the Secondary ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9694466/
59. [59] webThe KRAS-G12C inhibitor: activity and resistance - Nature https://www.nature.com/articles/s41417-021-00383-9
60. [60] webResistance to KRAS - Frontiers https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2021.787585/full
61. [61] webPDF Genetic mechanisms of resistance to targeted KRAS inhibition https://www.biorxiv.org/content/10.1101/2025.08.04.668444v1.full.pdf
62. [62] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.sciencedirect.com/science/article/pii/S1556086421021328
63. [63] webIn Silico Study of the Acquired Resistance Caused by the Secondary Mutations of KRAS G12C Protein Using Long Time Molecu https://pmc.ncbi.nlm.nih.gov/articles/PMC9694466/
64. [64] webRCSB PDB - 9O0R: Crystal structure of wild-type KRAS (GDP-bound) in ... https://www.rcsb.org/structure/9O0R
65. [65] webRCSB PDB - 6USZ: Identification of the Clinical Development Candidate ... https://www.rcsb.org/structure/6USZ
66. [66] webAdagrasib | C32H35ClFN7O2 | CID 138611145 - PubChem https://pubchem.ncbi.nlm.nih.gov/compound/Adagrasib
67. [67] webSynthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug ... https://www.sciencedirect.com/org/science/article/pii/S1523706023002493
68. [68] webSynthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug ... https://pubs.acs.org/doi/10.1021/acs.orglett.2c04266
69. [69] webPDF An In-depth Technical Guide to MRTX849 (Adagrasib): Chemical Structure ... https://pdf.benchchem.com/10857/An_In_depth_Technical_Guide_to_MRTX849_Adagrasib_Chemical_Structure_Properties_and_Therapeutic_Action.pdf
70. [70] webPDF The Structural Basis of KRAS G12C Inhibition by MRTX849: A Technical Guide https://pdf.benchchem.com/10857/The_Structural_Basis_of_KRAS_G12C_Inhibition_by_MRTX849_A_Technical_Guide.pdf
71. [71] webSynthesis of Adagrasib (MRTX849), a Covalent KRASG12C Inhibitor Drug ... https://www.semanticscholar.org/paper/Synthesis-of-Adagrasib-(MRTX849)%2C-a-Covalent-Drug-Chen-Lu/18dbb63b7a43573e8444b365dbd4fec53b142084
72. [72] dbeuropepmc · KRAS G12C switch-II pocket resistance mutation molecular dynamics conformational dynamics
73. [73] dbeuropepmc · KRAS G12C Y96D H95Q resistance mutation molecular dynamics simulation switch-II pocket conformational ensemble
74. [74] dbeuropepmc · KRAS G12C resistance mutation effector binding RAF RAS-binding domain reconfiguration signaling drug-bound
75. [75] webKRAS Secondary Mutations That Confer Acquired Resistance to KRAS G12C ... https://www.jto.org/article/S1556-0864(21)02132-8/fulltext
76. [76] webAcquired Resistance to KRAS G12C Inhibition in Cancer https://www.nejm.org/doi/full/10.1056/NEJMoa2105281
77. [77] webAcquired Resistance to KRASG12C Inhibition in Cancer https://www.nejm.org/doi/pdf/10.1056/NEJMoa2105281?listPDF=true
78. [78] webBeyond KRAS(G12C): Biochemical and Computational Characterization of ... https://pubs.acs.org/doi/full/10.1021/acschembio.4c00315
79. [79] webThe KRAS-G12C inhibitor: activity and resistance - Nature https://www.nature.com/articles/s41417-021-00383-9
80. [80] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
81. [81] webA saturation mutagenesis screen uncovers resistant and ... - PNAS https://www.pnas.org/doi/10.1073/pnas.2120512119
82. [82] webPDF Developing KRAS G12C Inhibitor-Resistant Tumor Models for Efficacy ... https://www.crownbio.com/hubfs/Assets2024/aacr-2024-posters/Crown-Bioscience-AACR24-Poster-1942-Developing-KRAS-G12C-Inhibitor-resistant-Tumor-Models-for-Efficacy-Evaluation-of-Next-generation-Anticancer-Therapies.pdf?hsLang=en
83. [83] webAcquired Resistance to KRASG12C Inhibition in Cancer - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC8864540/
84. [84] webMechanistic insights into the clinical Y96D mutation with ... - Frontiers https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.915512/full
85. [85] webMechanistic insights into the clinical Y96D mutation with acquired ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9399772/
86. [86] webIn Silico Study of the Acquired Resistance Caused by the Secondary ... https://pmc.ncbi.nlm.nih.gov/articles/PMC9694466/
87. [87] webMechanistic insights into the clinical Y96D mutation with acquired ... https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.915512/pdf?isPublishedV2=false
88. [88] webDecoding KRAS dynamics: Exploring the impact of mutations and inhibitor ... https://www.sciencedirect.com/science/article/pii/S0003986124004016
89. [89] webIn Silico Study of the Acquired Resistance Caused by the ... - MDPI https://www.mdpi.com/1422-0067/23/22/13845
90. [90] webIntegrating computational chemistry and machine learning to predict ... https://www.biorxiv.org/content/10.64898/2026.04.10.717640v1
91. [91] webBiophysical and structural analysis of KRAS switch-II pocket inhibitors ... https://www.sciencedirect.com/science/article/pii/S0021925825021817
92. [92] webMechanistic insights into the clinical Y96D mutation with acquired resistance to AMG510 in the KRASG12C - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC9399772/
93. [93] webKRAS interaction with RAF1 RAS-binding domain and cysteine ... - Nature https://www.nature.com/articles/s41467-021-21422-x
94. [94] webFrom G12C To pan-RAS: The expanding therapeutic landscape of https://www.sciencedirect.com/science/article/pii/S1040842826002313
95. [95] webIn situ RAS:RAF binding correlates with response to KRAS G12C ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11924342/
96. [96] webKRAS inhibitors: resistance drivers and combinatorial strategies https://www.sciencedirect.com/science/article/pii/S2405803324002759
97. [97] webThe KRAS-G12C inhibitor: activity and resistance - Nature https://www.nature.com/articles/s41417-021-00383-9
98. [98] webMore to the RAS Story: KRAS<sup>G12C</sup> Inhibition, Resistance ... https://ascopubs.org/doi/10.1200/EDBK_351333
99. [99] webKRAS Inhibitors (2026): The Complete Guide to Targeted Therapy ... https://cancer.aestheticsadvisor.com/2026/04/kras-inhibitors-2026-complete-guide-to.html
100. [100] webSRC kinase drives multidrug resistance induced by KRAS-G12C ... - AAAS https://www.science.org/doi/10.1126/sciadv.adq4274
101. [101] webA fresh look at covalent BTK inhibitor resistance https://ashpublications.org/blood/article/144/10/1029/517560/A-fresh-look-at-covalent-BTK-inhibitor-resistance
102. [102] webNovel mechanisms of resistance in CLL: variant BTK mutations in second ... https://www.sciencedirect.com/science/article/pii/S0006497125001375
103. [103] webBTK gatekeeper residue variation combined with cysteine 481 ... https://pmc.ncbi.nlm.nih.gov/articles/PMC8102192/
104. [104] webFunctional characterization of BTKC481S mutation that confers ibrutinib ... https://www.nature.com/articles/leu2014263
105. [105] webMicrosecond simulations to investigate the structural mechanism of ... https://www.nature.com/articles/s41598-025-24745-7
106. [106] webPirtobrutinib targets BTK C481S in ibrutinib-resistant CLL but second ... https://www.sciencedirect.com/science/article/pii/S2473952922007042
107. [107] webComprehensive Characterization of Bruton's Tyrosine Kinase Inhibitor ... https://pubs.acs.org/doi/10.1021/acsptsci.4c00540
108. [108] webPDF An In-depth Technical Guide to the BTK C481S Mutation and Inhibitor ... https://pdf.benchchem.com/15621/An_In_depth_Technical_Guide_to_the_BTK_C481S_Mutation_and_Inhibitor_Resistance.pdf

胶状淋巴系统驱动机制的多假说权衡与疾病关联：2025 年证据综合

摘要(立论)

2012 年 Iliff 等描述脑内存在一条依赖星形胶质细胞、沿血管旁间隙运行、由脑脊液(cerebrospinal fluid, CSF)驱动间质液(interstitial fluid, ISF)交换的废物清除途径——胶状淋巴系统(glymphatic system)<sup>11</sup>。此后十余年,围绕「CSF-ISF 流动究竟由什么驱动」这一问题,领域内先后提出动脉搏动驱动、AQP4(水通道蛋白-4)依赖、弥散质疑、去甲肾上腺素(norepinephrine, NE)-慢血管运动、以及搏动-跨膜压力协同等至少五种竞争或互补的假说。本报告基于对已检索文献的系统梳理,核心论点是:截至 2025 年,没有任何单一模型能解释全部证据;最接近完整的是「动脉搏动提供基础脉动 + 跨膜压力梯度提供净方向 + NE 驱动的慢血管运动放大睡眠期清除 + AQP4 作为水-力偶联器」的整合框架,而这一框架本身仍有可证伪的关键缺口。

---

一、核心机制:从动脉搏动到多动力协同

胶状淋巴系统的经典流体通路可概括为:CSF 自蛛网膜下腔沿动脉旁间隙进入脑实质 → 经星形胶质细胞血管足突上的 AQP4 进行 CSF-ISF 交换 → 间质液携带代谢废物(如淀粉样蛋白-β/Amyloid-β、tau)沿静脉旁间隙外流 → 经脑膜淋巴管引流至颈深淋巴结 <sup>235</sup>。这一通路在睡眠期显著增强,并受昼夜节律调控 <sup>1</sup>。

驱动这一流动的力学机制是长期争论的核心。Iliff 等最初提出动脉搏动驱动假说,认为脑动脉的周期性扩张为 CSF 沿动脉旁间隙内流提供动力 <sup>11</sup>。Mestre 等 2018 年用粒子追踪测速证实动脉搏动驱动了血管旁净流动,且高血压状态下搏动减弱与流速下降相关 <sup>14</sup>。AQP4 依赖模型则强调水通道的极化定位是 CSF-ISF 交换的关键 <sup>3</sup>。

2025 年,这一图景被显著精细化:Hauglund 等在 Cell 报告睡眠期 NE 水平的慢振荡驱动慢血管运动(slow vasomotion,约 0.1 Hz),进而放大胶状淋巴清除 <sup>7</sup>;Nozaleda 等的建模与实证研究提出动脉搏动与跨膜压力梯度(transmantle pressure)协同驱动血管旁间隙净流动 <sup>9</sup>。这些新证据并非否定动脉搏动模型,而是将其从「单一充分条件」降级为「必要但非充分条件」,并将解释重心移向多动力协同。

下图展示这一完整通路及增强/损伤节点。

graph LR
    A["蛛网膜下腔CSF"] -->|动脉搏动+跨膜压力| B["动脉旁间隙CSF内流"]
    B -->|AQP4介导水交换| C["CSF-ISF交换"]
    C --> D["间质液废物清除<br/>Aβ/tau"]
    D --> E["静脉旁间隙ISF外流"]
    E --> F["脑膜淋巴管引流"]
    F --> G["颈深淋巴结"]
    H["睡眠/NE-慢血管运动"] -.->|增强| B
    H -.->|增强| C
    I["衰老/血管硬化"] -.->|损伤| B
    I -.->|AQP4去极化| C
    J["AQP4极化"] -.->|维持| C

图注(机制通路图):胶状淋巴系统的流体通路与调控节点。实线箭头为 CSF/ISF 主流动方向;虚线箭头为调控关系。睡眠通过 NE-慢血管运动增强内流与交换 <sup>7</sup>,衰老与血管硬化则同时损伤动脉旁内流与 AQP4 极化 <sup>610</sup>。

---

二、五大驱动假说的系统权衡

我通过子智能体团队并行深挖了五种假说的核心主张、支持证据、反驳要点与可证伪实验。各假说的演化时间见下方时间线图。

2.1 假说演化时间线

如图1所示,胶状淋巴驱动机制的范式经历了从单一动脉搏动到多动力协同的连续精细化过程。

图1. 胶状淋巴驱动机制假说演化时间线(2012-2025)。横轴为年份,标注各假说奠基或关键支持文献。可见 2012-2018 年为单动力模型主导期(动脉搏动 <sup>11</sup>、AQP4 依赖 <sup>3</sup>),2020 年后转向争议与整合期(弥散质疑 [子智能体述及,原文未精确定位]、NE-慢血管运动 <sup>7</sup>、搏动-跨膜压力协同 <sup>9</sup>)。

2.2 各假说证据权衡

假说1:动脉搏动驱动(Iliff 2012/2013 <sup>11</sup>)。奠基假说。双光子成像示 CSF 沿穿透动脉旁间隙快速流入 <sup>11</sup>;Mestre 2018 粒子追踪定量证实搏动驱动、高血压时搏动减弱致流速下降 <sup>14</sup>。弱点:组织学切片示踪剂分布可能反映非生理固定事件(Mestre 2020 述评,子智能体引述);动脉搏动幅度有限,能否独立驱动足够净流动受质疑;睡眠期清除增强不能由搏动幅度增大解释。2025 年处境:仍为范式基础,但已被精细化为「必要非充分」。

假说2:AQP4 依赖(Mestre 2018 <sup>3</sup>)。AQP4 敲除小鼠清除显著降低 <sup>3</sup>;AQP4 极化有昼夜变化 <sup>1</sup>;AQP4 去极化与衰老/TBI/AD 模型清除受损相关 <sup>45</sup>。弱点:AQP4 是水通道,对溶质转运的直接机制不清;敲除效应可能部分源于血管动力学发育代偿。Zhu 等 2023 的 DCE-MRI 研究显示 H₂-¹⁷O(经 AQP4 的水)比 Gd-DTPA(溶质)转运更快更广,支持 AQP4 介导的是尺寸依赖性水转运而非直接溶质通道 [子智能体引述 Zhu 2023, DOI 10.1038/s41598-023-40896-x]。

假说3:弥散质疑(2023 年前后)。主张示踪剂动力学可由弥散解释,无需整体流动(bulk flow)。子智能体诚实标注:未能用工具精确定位该质疑论文原文;领域内对 bulk flow 的批判传统可见 Mestre 2020 述评指出「组织学示踪剂分布多反映非生理事件」。反驳:活体实时成像示方向性快速移动难由纯弥散解释 <sup>14</sup>;不同尺寸示踪剂转运速度差异提示尺寸选择性 [Zhu 2023]。2025 年处境:边缘但具批判价值,Hauglund 与 Nozaleda 的整合模型部分回应了该质疑。

假说4:NE-慢血管运动(Hauglund 2025 Cell <sup>7</sup>)。睡眠期 NE 波动与慢血管运动耦合、驱动清除 <sup>7</sup>。弱点:慢血管运动频率(约 0.1 Hz)远低于心搏,流体力学机制需进一步定量;NE 也影响 AQP4 极化与脑血流,难排除间接效应。2025 年处境:新兴、受关注,是动脉搏动模型在睡眠期的重要精细化。

假说5:搏动+跨膜压力协同(Nozaleda 2025 <sup>9</sup>)。动脉搏动与跨膜压力梯度协同驱动净流动 <sup>9</sup>,与 Bohr 2022 建模综述的多动力思路一致 [子智能体引述, DOI 10.1016/j.isci.2022.105569]。弱点:跨膜压力梯度活体测量困难,多为建模推断;协同的相对贡献需定量分离。2025 年处境:整合性新模型,体现领域从单动力向多动力协同的转向。

2.3 假说间关系

下图展示五大假说并非简单对立,而是部分互补、部分伪对立的关系网络。

图注(假说关系网络):绿/正号边表示协同或增强关系,红/负号边表示反驳或抑制关系。动脉搏动与跨膜压力、NE-慢血管运动为协同非互斥;弥散质疑同时反驳动脉搏动与 AQP4 模型;AQP4 依赖与动脉搏动为互补(水通道实现水力偶联)而非替代;衰老通过 AQP4 去极化间接抑制清除。

---

三、胶状淋巴清除效率的定量证据

为可视化不同生理/病理状态下胶状淋巴清除效率的相对变化,我汇总了已检索文献报告的方向性证据,绘制图2。

图2. 不同生理/病理状态下胶状淋巴清除效率相对变化(相对清醒基线)。增强组:睡眠期清除显著高于清醒期 <sup>51</sup>;自主运动促进 Aβ 清除并降低星形胶质细胞/小胶质细胞活化 [子智能体引述 He 2017];NE-慢血管运动驱动睡眠期清除 <sup>7</sup>。受损组:衰老清除下降 <sup>5</sup>;AD 模型 Aβ/tau 清除受损 <sup>4</sup>;高血压减弱动脉搏动致流速下降 <sup>14</sup>;TBI 后清除受损促进 tau 病理 <sup>15</sup>。数值标注说明:本图为定性-半定量汇总,各条目方向(增强/受损)有文献支持,但具体倍数在不同研究间因测量方法(双光子荧光强度、DCE-MRI 信号、粒子追踪速度)与模型不同而不可直接比较;图中刻度代表文献报告趋势的相对位置,非绝对清除率。

关键定量发现(方向性):

• 睡眠增强:睡眠期胶状淋巴清除显著高于清醒期,这是 2013 年 Xie 等 Science 工作与后续多项研究的核心发现,被 Nedergaard/Goldman 2020 综述归纳为「睡眠-清除偶联」<sup>5</sup>。
• 衰老与疾病受损:衰老伴随 AQP4 去极化与清除下降 <sup>5</sup>;AD 模型中胶状淋巴功能受损与 tau 清除障碍相关 <sup>4</sup>;TBI 后胶状淋巴受损促进 tau 病理 <sup>15</sup>。
• NE-慢血管运动:2025 年 Hauglund 等直接将睡眠期清除增强归因于 NE 振荡驱动的慢血管运动 <sup>7</sup>,为睡眠-清除偶联提供了机制层级的解释。

---

四、疾病关联:从胶状淋巴障碍到痴呆终末通路

Nedergaard 与 Goldman 2020 在 Science 提出「胶状淋巴障碍是痴呆的最终共同通路」假说 <sup>5</sup>,核心逻辑是:睡眠质量随龄下降、睡眠结构破坏常先于痴呆发生、而睡眠期正是胶状淋巴清除最强时段,因此清除障碍→Aβ/tau 蓄积→神经退行性病变构成因果链条。支持证据包括 AD 模型中胶状淋巴清除受损与 tau 清除障碍 <sup>4</sup>、TBI 后清除受损促进 tau 病理 <sup>15</sup>、以及衰老相关清除下降 <sup>5</sup>。

但该终末通路假说仍需因果强化:(1)多数证据为相关性(清除下降与病理蓄积共存),清除下降是原因还是结果未完全确立;(2)人体验证依赖新兴 MRI 技术,2025 年综述指出非侵入性 MRI 评估仍在快速发展中 <sup>8</sup>,尚无统一标准;(3)从清除障碍到临床痴呆的时序与剂量-效应关系尚缺。

衰老相关机制的新进展:2025 年 Herzog 等综述动脉硬化与血管衰老机制 <sup>6</sup>,Santisteban 与 Iadecola 综述神经血管衰老病理生物学 <sup>10</sup>,二者共同提示血管硬化→动脉搏动减弱→胶状淋巴驱动下降这一上游链条,与衰老清除下降的临床观察形成机制闭环。

---

五、新颖点:多动力整合框架与可证伪预测

本文相对现有工作的新增在于:基于 2025 年最新两篇关键文献(Hauglund Cell <sup>7</sup>、Nozaleda Sci Rep <sup>9</sup>),明确提出一个多动力分层整合框架,并给出各假说间的「伪对立」判断:动脉搏动 vs NE-慢血管运动非对立(NE 波动调控血管运动幅度,是对搏动驱动的调制);动脉搏动 vs 跨膜压力为协同;AQP4 依赖与整体流动非互斥(AQP4 可能是整体流动的水力实现);弥散质疑与对流模型可能在不同空间尺度(血管旁大间隙 vs 实质微间隙)分别成立。

该框架的可证伪预测:

1. 若同时消除动脉搏动与 NE 波动但保持跨膜压力梯度,清除率应部分保留(验证跨膜压力的独立贡献);
2. AQP4 急性阻断应选择性损害水(H₂-¹⁷O)转运而对大分子溶质(Gd-DTPA)影响较小(验证 AQP4 是水-力偶联器而非溶质通道);
3. 若弥散质疑成立,无外部注入梯度下局部光解释放示踪剂应呈各向同性分布,无沿血管旁方向性偏移。

---

六、验证方案(三阶验证)

1. 多动力分离实验:同一活体动物分别消除动脉搏动(主动脉短暂阻断)、NE 波动(蓝斑药理/光遗传抑制)、跨膜压力梯度(脑室-腰池压力平衡),双光子高时空分辨率粒子追踪测各条件下血管旁净流速,定量分离各驱动力相对贡献。
2. caged tracer 弥散-对流区分实验:脑实质局部双光子光解释放 caged 荧光示踪剂(无外部注入梯度),测量无扰动生理状态下各向同性弥散 vs 沿血管旁间隙方向性偏移,直接区分弥散与对流,回应 2023 弥散质疑。
3. AQP4 急性阻断+水/溶质双示踪实验:急性 AQP4 阻断剂(非基因敲除)下同时追踪 H₂-¹⁷O(水)与 Gd 类(溶质),测试 AQP4 是否为尺寸选择性水通道,而非通过发育代偿间接影响清除。

---

七、诚实的局限

1. 弥散质疑原文定位失败:子智能体未能用工具精确定位「Jiang 等 2023 弥散质疑」的原文标题与 DOI,该假说的证据描述基于领域述评间接引述,引用强度弱于其他假说。
2. 定量刻度局限:图2 的清除效率相对变化为定性-半定量汇总,不同研究测量方法与模型不统一,具体数值不可直接横向比较;图中刻度为趋势相对位置而非绝对清除率。
3. 因果性不足:胶状淋巴障碍与神经退行性病变的多为相关证据,清除下降→痴呆的因果链条尚缺前瞻性临床验证。
4. 人体证据薄弱:多数机制证据来自啮齿类,人体非侵入性 MRI 评估仍在发展 <sup>8</sup>,尚未建立统一标准。
5. 整合框架为假说:多动力整合框架本身尚未被单一实验直接验证,其各动力相对贡献的预测有待实验检验。

---

八、后续可深化的方向

• 精确定位 2023 年弥散质疑论文原文,完成对该假说的直接证据评估;
• 用 DCE-MRI 公开数据集(如 Hablitz/Benveniste 团队相关大鼠数据)对多动力框架做定量拟合,给出各动力贡献的数值估计;
• 检索 2024-2025 年人体 MRI 胶状淋巴研究,评估清除障碍作为 AD 早期生物标志物的临床证据等级;
• 梳理运动/睡眠干预增强胶状淋巴清除的人体转化证据,评估治疗靶点可行性。

---

参考文献

• <sup>1</sup> Hablitz LM, Plá V, Giannetto M, et al. Circadian control of brain glymphatic and lymphatic fluid flow. Nat Commun. 2020. DOI: 10.1038/s41467-020-18115-2
• <sup>2</sup> Rasmussen MK, Mestre H, Nedergaard M. The glymphatic pathway in neurological disorders. Lancet Neurol. 2018. DOI: 10.1016/s1474-4422(18)30318-1
• <sup>3</sup> Mestre H, Hablitz LM, Xavier ALR, et al. Aquaporin-4-dependent glymphatic solute transport in the rodent brain. eLife. 2018. DOI: 10.7554/elife.40070
• <sup>4</sup> Harrison IF, Ismail O, Machhada A, et al. Impaired glymphatic function and clearance of tau in an Alzheimer's disease model. Brain. 2020. DOI: 10.1093/brain/awaa179
• <sup>5</sup> Nedergaard M, Goldman SA. Glymphatic failure as a final common pathway to dementia. Science. 2020. DOI: 10.1126/science.abb8739
• <sup>6</sup> Herzog MJ, Müller P, Lechner K, et al. Arterial stiffness and vascular aging: mechanisms, prevention, and therapy. Signal Transduct Target Ther. 2025. DOI: 10.1038/s41392-025-02346-0
• <sup>7</sup> Hauglund N, Andersen M, Tokarska K, et al. Norepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep. Cell. 2025. DOI: 10.1016/j.cell.2024.11.027
• <sup>8</sup> Botta D, Hutuca I, El Ghoul E, et al. Emerging non-invasive MRI techniques for glymphatic system assessment in neurodegenerative disease. J Neuroradiol. 2025. DOI: 10.1016/j.neurad.2025.101322
• <sup>9</sup> Nozaleda GL, Coenen W, Haughton VM, et al. Arterial pulsations and transmantle pressure synergistically drive glymphatic flow. Sci Rep. 2025. DOI: 10.1038/s41598-025-97631-x
• <sup>10</sup> Santisteban MM, Iadecola C. The pathobiology of neurovascular aging. Neuron. 2025. DOI: 10.1016/j.neuron.2024.12.014
• <sup>11</sup> Iliff JJ, et al. A paravascular pathway facilitates CSF flow through the brain parenchyma and the clearance of interstitial solutes. (双光子成像, 2013). DOI: 10.1523/JNEUROSCI.1592-13.2013
• <sup>14</sup> Mestre H, et al. (粒子追踪测速, 2018). DOI: 10.1038/s41467-018-07318-3
• <sup>15</sup> Iliff JJ, Chen M, Plog BA, et al. Impairment of glymphatic pathway function promotes tau pathology after traumatic brain injury. J Neurosci. 2014. DOI: 10.1523/JNEUROSCI.3020-14.2014
• [Zhu 2023] (H₂-¹⁷O vs Gd-DTPA 尺寸依赖性转运, DCE-MRI). DOI: 10.1038/s41598-023-40896-x
• [Bohr 2022] (胶状淋巴建模综述, 对流 vs 弥散张力). DOI: 10.1016/j.isci.2022.105569
• [He 2017] He X, Liu D, Zhang Q, et al. Voluntary exercise promotes glymphatic clearance of amyloid beta and reduces the activation of astrocytes and microglia in aged mice.
• [Xie 2013] Xie L, et al. Sleep drives metabolite clearance from the adult brain. Science. 2013.

计算得到的图 · Computed figures

图1

图2

产物文件 · Files produced

• fig2_clearance_efficiency.png — 92.7 KB
• glymphatic_timeline.png — 159.0 KB

参考文献 · References

1. [1] paperCircadian control of brain glymphatic and lymphatic fluid flow https://doi.org/10.1038/s41467-020-18115-2
2. [2] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
3. [3] paperAquaporin-4-dependent glymphatic solute transport in the rodent brain https://doi.org/10.7554/elife.40070
4. [4] paperImpaired glymphatic function and clearance of tau in an Alzheimer’s disease model https://doi.org/10.1093/brain/awaa179
5. [5] paperGlymphatic failure as a final common pathway to dementia https://doi.org/10.1126/science.abb8739
6. [6] paperArterial stiffness and vascular aging: mechanisms, prevention, and therapy https://doi.org/10.1038/s41392-025-02346-0
7. [7] paperNorepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep https://doi.org/10.1016/j.cell.2024.11.027
8. [8] paperEmerging non-invasive MRI techniques for glymphatic system assessment in neurodegenerative disease https://doi.org/10.1016/j.neurad.2025.101322
9. [9] paperArterial pulsations and transmantle pressure synergetically drive glymphatic flow https://doi.org/10.1038/s41598-025-97631-x
10. [10] paperThe pathobiology of neurovascular aging https://doi.org/10.1016/j.neuron.2024.12.014
11. [11] paperCerebral Arterial Pulsation Drives Paravascular CSF–Interstitial Fluid Exchange in the Murine Brain https://doi.org/10.1523/jneurosci.1592-13.2013
12. [12] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
13. [13] paperThe Brain’s Glymphatic System: Current Controversies https://doi.org/10.1016/j.tins.2020.04.003
14. [14] paperFlow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension https://doi.org/10.1038/s41467-018-07318-3
15. [15] paperImpairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury https://doi.org/10.1523/jneurosci.3020-14.2014
16. [16] paperNorepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep https://doi.org/10.1016/j.cell.2024.11.027
17. [17] paperCerebral Edema Formation After Stroke: Emphasis on Blood–Brain Barrier and the Lymphatic Drainage System of the Brain https://doi.org/10.3389/fncel.2021.716825
18. [18] paperGlymphatic system and psychiatric disorders: need for a new paradigm? https://doi.org/10.3389/fpsyt.2025.1642605
19. [19] paperDiffusion magnetic resonance imaging of cerebrospinal fluid dynamics: Current techniques and future advancements https://doi.org/10.1002/nbm.5162
20. [20] paperContributions of blood–brain barrier imaging to neurovascular unit pathophysiology of Alzheimer’s disease and related dementias https://doi.org/10.3389/fnagi.2023.1111448
21. [21] webNeurofluids and the glymphatic system: anatomy, physiology, and imaging https://academic.oup.com/bjr/article/96/1151/20230016/7499031
22. [22] webThe Association between Glymphatic System and Perivascular Macrophages ... https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10602168/
23. [23] webTransport pathways and kinetics of cerebrospinal fluid tracers ... - Nature https://www.nature.com/articles/s41598-023-40896-x
24. [24] webEmerging non-invasive MRI techniques for glymphatic system assessment ... https://www.sciencedirect.com/science/article/pii/S015098612500080X
25. [25] webThe glymphatic system's role in traumatic brain injury-related ... https://www.nature.com/articles/s41380-023-02070-7
26. [26] webNew perspectives on the glymphatic system and the relationship between ... https://www.sciencedirect.com/science/article/pii/S0969996125000075
27. [27] webGlymphatic system: a self-purification circulation in brain https://www.frontiersin.org/journals/cellular-neuroscience/articles/10.3389/fncel.2025.1528995/full
28. [28] webThe glymphatic system: Current understanding and modeling https://www.cell.com/iscience/fulltext/S2589-0042(22)01259-7
29. [29] webTransport pathways and kinetics of cerebrospinal fluid tracers in mouse brain observed by dynamic contrast-enhanced MRI https://www.nature.com/articles/s41598-023-40896-x
30. [30] paperAquaporin-4-dependent glymphatic solute transport in the rodent brain https://doi.org/10.7554/elife.40070
31. [31] paperEvaluating glymphatic pathway function utilizing clinically relevant intrathecal infusion of CSF tracer https://doi.org/10.1186/1479-5876-11-107
32. [32] paperGlymphatic imaging using MRI https://doi.org/10.1002/jmri.26892
33. [33] paperSpatial model of convective solute transport in brain extracellular space does not support a “glymphatic” mechanism https://doi.org/10.1085/jgp.201611684
34. [34] paperNorepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep https://doi.org/10.1016/j.cell.2024.11.027
35. [35] paperNorepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep https://doi.org/10.1016/j.cell.2024.11.027
36. [36] paperCerebral Edema Formation After Stroke: Emphasis on Blood–Brain Barrier and the Lymphatic Drainage System of the Brain https://doi.org/10.3389/fncel.2021.716825
37. [37] paperGlymphatic system and psychiatric disorders: need for a new paradigm? https://doi.org/10.3389/fpsyt.2025.1642605
38. [38] paperMeasuring glymphatic function: Assessing the toolkit https://doi.org/10.4103/nrr.nrr-d-24-01013
39. [39] paperThe Collapse of Brain Clearance: Glymphatic-Venous Failure, Aquaporin-4 Breakdown, and AI-Empowered Precision Neurotherapeutics in Intracranial Hypertension https://doi.org/10.3390/ijms26157223
40. [40] webHuman brain solute transport quantified by glymphatic MRI-informed ... https://link.springer.com/article/10.1186/s12987-023-00459-8
41. [41] webMapping the Glymphatic Pathway Using Imaging Advances - MDPI https://www.mdpi.com/2571-8800/6/3/31
42. [42] webNeurofluids and the glymphatic system: anatomy, physiology, and imaging https://academic.oup.com/bjr/article/96/1151/20230016/7499031
43. [43] webDiffusion Tensor Imaging in Neurofluids - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11986261/
44. [44] webProgress in magnetic resonance imaging of the glymphatic system https://www.sciencedirect.com/science/article/pii/S2772516224000615
45. [45] webThe Glymphatic system: A dynamic regulator of brain health and ... https://www.sciencedirect.com/science/article/pii/S0014488626001895
46. [46] webThe glymphatic system: a new perspective on brain diseases https://pmc.ncbi.nlm.nih.gov/articles/PMC10308198/
47. [47] webNoninvasive investigations of human glymphatic dynamics in a ... - Springer https://link.springer.com/article/10.1007/s00330-023-09894-5
48. [48] webPubMed https://pubmed.ncbi.nlm.nih.gov/
49. [49] webNeurofluids and the glymphatic system: anatomy, physiology, and imaging https://academic.oup.com/bjr/article/96/1151/20230016/7499031
50. [50] webEmerging non-invasive MRI techniques for glymphatic system assessment ... https://www.sciencedirect.com/science/article/pii/S015098612500080X
51. [51] webHuman brain solute transport quantified by glymphatic MRI-informed ... https://link.springer.com/article/10.1186/s12987-023-00459-8
52. [52] webDiffusion Tensor Imaging in Neurofluids - PMC https://pmc.ncbi.nlm.nih.gov/articles/PMC11986261/
53. [53] webNoninvasive investigations of human glymphatic dynamics in a ... - Springer https://link.springer.com/article/10.1007/s00330-023-09894-5
54. [54] webThe glymphatic system: a new perspective on brain diseases https://pmc.ncbi.nlm.nih.gov/articles/PMC10308198/
55. [55] webAdvances in Imaging the Glymphatic System https://www.advancesinclinicalradiology.com/article/S2589-8701(25)00010-0/fulltext
56. [56] paperFlow of cerebrospinal fluid is driven by arterial pulsations and is reduced in hypertension https://doi.org/10.1038/s41467-018-07318-3
57. [57] paperCerebral Arterial Pulsation Drives Paravascular CSF–Interstitial Fluid Exchange in the Murine Brain https://doi.org/10.1523/jneurosci.1592-13.2013
58. [58] paperThe Brain’s Glymphatic System: Current Controversies https://doi.org/10.1016/j.tins.2020.04.003
59. [59] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
60. [60] paperCircadian control of brain glymphatic and lymphatic fluid flow https://doi.org/10.1038/s41467-020-18115-2
61. [61] webThe Brain's Glymphatic System: Current Controversies - PubMed https://pubmed.ncbi.nlm.nih.gov/?term=Mestre+2020+glymphatic+current+controversies
62. [62] dbeuropepmc · Mestre 2020 Brain Glymphatic System Current Controversies
63. [63] webTransport pathways and kinetics of cerebrospinal fluid tracers ... - Nature https://www.nature.com/articles/s41598-023-40896-x
64. [64] webNeuronal dynamics direct cerebrospinal fluid perfusion and brain ... https://www.nature.com/articles/s41586-024-07108-6
65. [65] webNeurofluids and the glymphatic system: anatomy, physiology, and imaging https://academic.oup.com/bjr/article/96/1151/20230016/7499031
66. [66] webHuman brain solute transport quantified by glymphatic MRI-informed ... https://link.springer.com/article/10.1186/s12987-023-00459-8
67. [67] webThe Glymphatic system: A dynamic regulator of brain health and ... https://www.sciencedirect.com/science/article/pii/S0014488626001895
68. [68] webThe glymphatic system: a new perspective on brain diseases https://www.frontiersin.org/journals/aging-neuroscience/articles/10.3389/fnagi.2023.1179988/full
69. [69] webA SPECT-based method for dynamic imaging of the glymphatic system in ... https://journals.sagepub.com/doi/10.1177/0271678X231156982
70. [70] webPhysiological brain clearance architecture revealed by neuronal protein ... https://www.cell.com/cell/fulltext/S0092-8674(26)00515-5
71. [71] webTransport pathways and kinetics of cerebrospinal fluid tracers in mouse brain observed by dynamic contrast-enhanced MRI https://www.nature.com/articles/s41598-023-40896-x
72. [72] paperAquaporin-4-dependent glymphatic solute transport in the rodent brain https://doi.org/10.7554/elife.40070
73. [73] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
74. [74] paperThe role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system? https://doi.org/10.1007/s00401-018-1812-4
75. [75] paperImpairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury https://doi.org/10.1523/jneurosci.3020-14.2014
76. [76] paperImpaired glymphatic function and clearance of tau in an Alzheimer’s disease model https://doi.org/10.1093/brain/awaa179
77. [77] paperThe role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system? https://doi.org/10.1007/s00401-018-1812-4
78. [78] paperAquaporin-4-dependent glymphatic solute transport in the rodent brain https://doi.org/10.7554/elife.40070
79. [79] paperRapid lymphatic efflux limits cerebrospinal fluid flow to the brain https://doi.org/10.1007/s00401-018-1916-x
80. [80] paperCerebrospinal Fluid Flow https://doi.org/10.1146/annurev-fluid-120720-011638
81. [81] paperCrossTalk proposal: The glymphatic system supports convective exchange of cerebrospinal fluid and brain interstitial fluid that is mediated by perivascular aquaporin‐4 https://doi.org/10.1113/jp277635
82. [82] paperBlood-Brain Barrier: From Physiology to Disease and Back https://doi.org/10.1152/physrev.00050.2017
83. [83] paperNorepinephrine-mediated slow vasomotion drives glymphatic clearance during sleep https://doi.org/10.1016/j.cell.2024.11.027
84. [84] paperGlymphatic system dysfunction predicts amyloid deposition, neurodegeneration, and clinical progression in Alzheimer's disease https://doi.org/10.1002/alz.13789
85. [85] paperGlymphatic imaging: a critical look at the DTI-ALPS index https://doi.org/10.1007/s00234-023-03270-2
86. [86] paperDiffusion Tensor Image Analysis ALong the Perivascular Space (DTI-ALPS): Revisiting the Meaning and Significance of the Method https://doi.org/10.2463/mrms.rev.2023-0175
87. [87] paperAquaporin-4-dependent glymphatic solute transport in the rodent brain https://doi.org/10.7554/elife.40070
88. [88] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
89. [89] paperCircadian control of brain glymphatic and lymphatic fluid flow https://doi.org/10.1038/s41467-020-18115-2
90. [90] paperImpairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury https://doi.org/10.1523/jneurosci.3020-14.2014
91. [91] paperThe role of brain barriers in fluid movement in the CNS: is there a ‘glymphatic’ system? https://doi.org/10.1007/s00401-018-1812-4
92. [92] paperThe glymphatic pathway in neurological disorders https://doi.org/10.1016/s1474-4422(18)30318-1
93. [93] paperGlymphatic failure as a final common pathway to dementia https://doi.org/10.1126/science.abb8739
94. [94] paperImpairment of Glymphatic Pathway Function Promotes Tau Pathology after Traumatic Brain Injury https://doi.org/10.1523/jneurosci.3020-14.2014
95. [95] paperThe Glymphatic System and Waste Clearance with Brain Aging: A Review https://doi.org/10.1159/000490349
96. [96] paperCircadian control of brain glymphatic and lymphatic fluid flow https://doi.org/10.1038/s41467-020-18115-2